Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma

NCT01177397 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT01177397
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01177397 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Lead sponsor
Celgene
Phase
Phase 1/2
Overall status
Completed
Start date
July 20, 2010
Completion date
December 9, 2016
Enrollment
226 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma, glioblastoma multiforme, hepatocellular carcinoma, hormone receptor-positive breast cancer, multiple myeloma, neuroendocrine tumors of non-pancreatic origin, non-small cell lung cancer